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Despite recent advances in critical care, the overallmortality of adult respiratory distress syndrome
(ARDS) remains approximately 50%.1,2 Mechanical
ventilation can cause iatrogenic injury to the lungs by
inflicting barotrauma and volutrauma3-6 to the small frac-
tion of compliant alveoli and by the activation of inflam-
matory mediators, which may aggravate ARDS.7-9 By
way of reducing ventilator-induced lung injury, recent
trends in ventilator management limit inflation pres-
sures and tidal volumes, often with a rise in systemic
arterial carbon dioxide (CO2),10 termed “permissive
hypercapnia.” Lung protective ventilator strategies have
Objective: Arteriovenous carbon dioxide removal (AVCO2R) uses a simple
arteriovenous shunt for CO2 removal to minimize barotrauma/volutrauma
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comes study of AVCO2R in our new, clinically relevant model of respiratory
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40% third-degree burn. When respiratory distress syndrome developed
(PaO2/FIO2 < 200 at 40 to 48 hours), animals were randomized to the
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been shown to reduce the incidence of barotrauma/
volutrauma and possibly improve survival in
ARDS.11,12
We13 have shown that arteriovenous CO2 removal
(AVCO2R) allows significant reductions in ventilator
pressures without hypercapnia or the complex circuitry
and monitoring required for extracorporeal membrane
oxygenation (ECMO) in sheep. Arterial percutaneous
cannulas of 10F to 14F allow adequate blood flow to
achieve near total CO2 removal without incurring
hypercapnia in adult sheep.14,15 In this current study,
we used our recently established, clinically relevant
LD50 large animal model of respiratory distress syn-
drome (ARDS) induced by a 40% full-thickness cuta-
neous flame burn and a moderately severe smoke
inhalation injury.16 To evaluate algorithm-directed,
pressure-limited ventilator management with and with-
out percutaneous AVCO2R, we designed a prospective
randomized nonblinded outcomes study with the pri-
mary end points of ventilator-free/ventilator-dependent
days and survival. Secondary end points included
AVCO2R flow and CO2 removal, hemodynamic pa-
rameters (heart rate, mean arterial pressure, pulmonary
artery pressure, pulmonary artery wedge pressure, and
cardiac output), ventilator parameters (tidal volume,
peak inspiratory pressure, respiratory rate, and inspired
oxygen fraction [FIO2]), complications, and necropsy
findings.
Materials and methods
All animals received humane care according to the
“Guide for the Care and Use of Laboratory Animals” pre-
pared by the Institute of Laboratory Animal Resources,
National Research Council, and published by the National
Academy Press, revised 1996. The study was approved by
the Institutional Animal Care and Use Committee (IACUC)
of The University of Texas Medical Branch, Galveston,
Texas, with strict adherence to IACUC guidelines regarding
humane use of animals.
Adult Suffolk ewes (n = 18, 29.5-45 kg) were instrument-
ed with femoral arterial and venous catheters and a pul-
monary arterial catheter 2 days before injury. Baseline vari-
ables including heart rate, cardiac output, mean arterial
pressure, pulmonary artery pressure, central venous pressure,
pulmonary artery wedge pressure, and arterial and venous
blood gases were obtained immediately before injury.
After endotracheal intubation, 1% to 2.5% halothane was
administered via an anesthesia ventilator (Ohmeda 7000;
BOC Health Care, Liberty Corner, NJ). To induce ARDS, we
performed a third-degree cutaneous flame burn on 40% of the
total body surface area (20% on each side of the animal) with
36 breaths of cotton smoke insufflation delivered between the
two burn episodes.16 Animals recovered from anesthesia and
were mechanically ventilated (Servo 900C; Siemens-Elema,
Sweden). Initial post-injury ventilator settings were as fol-
lows: respiratory rate 25 to 30 breaths/min, tidal volume 15
mL/kg, FIO2 1.0, and positive end-expiratory pressure 5 cm
H2O. Fluid resuscitation used lactated Ringer’s solution as
determined by the Parkland formula.17 FIO2 was reduced
(once carboxyhemoglobin was below 10% of baseline) to
maintain a PaO2 more than 60 mm Hg. Arterial and mixed
venous blood gases were measured every 6 hours, with
minute ventilation and FIO2 adjusted to maintain arterial pH
7.35 to 7.45, PaO2 more than 60 mm Hg, and PaCO2 less than
40 mm Hg. Hemodynamic variables and ventilator settings,
including minute ventilation and peak inspiratory pressure,
were recorded every 6 hours. Airway suctioning and lavage
were performed every 4 to 6 hours to remove proteinaceous
bronchial casts.
Fig 1. Schematic of model using the simple AVCO2R circuit with low-resistance membrane gas exchanger in
mechanically ventilated smoke/burn-injured sheep.
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Animals were randomized to AVCO2R (n = 9) or sham 
(n = 9) groups when they met entry criteria for ARDS
(PaO2/FIO2 < 200), generally within 40 to 48 hours of injury.
Animals randomized to the AVCO2R group were reanes-
thetized, systemically anticoagulated (300 IU/kg bovine
lung heparin; Upjohn, Kalamazoo, Mich), and started on
antibiotic therapy (ampicillin, 1 g; gentamicin, 80 mg/mL).
Animals then underwent cannulation of the left carotid
artery (percutaneous 10F TF018LH; Research Medical,
Midvale, Utah) and the left jugular vein (percutaneous 14F
TF022L; Research Medical). A commercially available,
low-resistance membrane gas exchanger (Affinity; Avecor
Cardiovascular, Plymouth, Minn) was primed with normal
saline solution (270 mL) and connected to the vascular can-
nulas (Fig 1). Activated clotting time (ACT, Hemochron
400; International Technidyne, Edison, NJ) was maintained
between 300 and 500 seconds with a continuous heparin
infusion throughout the study. The animal was then placed
on a volume-controlled ventilator (Bear 1000 Ventilator;
Bear Medical Systems, Inc, Riverside, Calif) before initia-
tion of AVCO2R. Animals randomized to the sham group
underwent the identical management and operative expo-
sure, with ligation of the carotid artery and jugular vein, but
were not cannulated for AVCO2R.
After the initiation of AVCO2R flow with extracorporeal CO2
removal, minute ventilation was reduced in a stepwise fashion
according to our algorithm (Fig 2). Initial reductions were made
in tidal volume (20% reduction) to reduce the peak inspiratory
pressure below 30 cm H2O. Once targeted airway pressures
were achieved, respiratory rate was incrementally reduced to
allow a longer respiratory cycle and gentle inspiratory flow if
PaCO2 was 40 mm Hg or less. To minimize atelectasis, the re-
spiratory rate was not reduced below 2 breaths per minute.
Concurrently, FIO2 was reduced as PaO2 remained above a
threshold of 60 mm Hg. Positive end-expiratory pressure was
kept at 5 cm H2O throughout the study. When PaO2 could be
maintained above 60 mm Hg on an FIO2 of 0.21 and a continu-
ous positive airway pressure of 7 cm H2O, animals were
weaned from the ventilator. Daily measurements of heart rate,
cardiac output, mean arterial pressure, pulmonary artery pres-
sure, blood flow, peak inspiratory pressure, and CO2 removal
were recorded, and systemic and pulmonary vascular resistance
were calculated and compared with baseline measurements.
AVCO2R blood flow was monitored by an ultrasonic flow
probe (model H6X; Transonic Systems, Ithaca, NY) on the
arterial cannula interfaced with a real-time flowmeter (model
HT 109; Transonic Systems) with digital display. The arterio-
venous pressure gradient across the gas exchanger was calcu-
lated on the basis of difference between the inlet and outlet
pressures. Sweep gas flow (100% oxygen) was controlled by
an in-line regulator and set at 1.5 to 2.0 times blood flow. CO2
removal by the device was calculated as the product of gas
flow and its exhaust CO2 concentration measured by an in-
line capnometer (SaraTrans, Lenexa, Kan). CO2 removal by
the native lungs was calculated as the product of minute ven-
tilation and the CO2 concentration in the expired gas collect-
ed in a Douglas bag. Blood and expired gases were measured
with a blood gas system (System BG3 and Co-Oxymeter 482;
Instrumentation Laboratory, Lexington, Mass). The animals
received 24-hour bedside care and remained mechanically
ventilated for 7 days or until successfully weaned from ven-
tilator support. The management of both groups of animals
was reviewed by a pulmonologist/intensivist (A.B.) for con-
sistency of care and adherence to the algorithm.
Fig 2.  Management algorithm for ventilator reductions with AVCO2R. ARDS, Adult respiratory distress syndrome;
P/F, PaO2/FIO2 ratio; TV, tidal volume; PIP, peak inspiratory pressure; RR, respiratory rate; PEEP, peak end-expi-
ratory pressure; CPAP, continuous positive airway pressure.
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Data are expressed as mean ± SEM and were displayed and
analyzed by SigmaPlot and SigmaStat (Jandel Scientific, San
Rafael, Calif). Comparisons with baseline (before injury)
were made by 1-way analysis of variance with Dunnett’s test,
with time treated as repeated measures. Survival, ventilator-
free days, and ventilator-dependent days as primary end
points and applicable secondary end points were compared
between the 2 groups of animals with the Student t test.
Results
A total of 2946 animal-hours of bedside critical care
and 696 total hours of AVCO2R were required for this
study. Ninety percent compliance with the study proto-
col was maintained during the trial. There were no sig-
nificant changes in hemodynamics throughout the study
despite the arteriovenous shunt. In the AVCO2R group,
there was no significant change in blood flow or pres-
sure gradient across the device (always less than 10 mm
Hg) throughout the experiment. For the primary end
points, the AVCO2R group averaged 3.9 ventilator-free
days compared with 0.2 for the sham group (P < .05).
Likewise, the AVCO2R group averaged 2.4 ventilator-
dependent days whereas all 3 survivors in the sham
group were still ventilator dependent at day 7 (average
6.2 [P < .05]). All 8 animals in the AVCO2R group sur-
vived the 7-day study, whereas only 3 of 8 animals in
the sham group survived 7 days (P < .05). One animal
died in each group from technical complications during
model development and both were excluded from
analysis. One AVCO2R animal had minor bleeding from
the neck, which was relieved with pressure. 
Despite the arteriovenous shunt, the measured para-
meters of heart rate, mean arterial pressure, cardiac
output, and pulmonary artery wedge pressure remained
relatively constant and were not statistically different
from baseline at any time point during the study. The
extracorporeal flow rate and cardiac output are seen in
Fig 3. Blood flow through the oxygenator ranged from
821.4 ± 55.4 mL/min to 970.2 ± 45.1 mL/min and aver-
aged 869.9 ± 23.2 mL/min or 13.2 ± 0.7% of the car-
diac output. As seen in previous studies, the pressure
gradient across the device was less than 10 mm Hg
throughout the study. CO2 removal in relation to PaCO2
is shown in Fig 4. CO2 removal via AVCO2R (up to day
5) ranged from 91.5 ± 22.1 to 116.4 ± 13.7 mL/min
(93%-97% of CO2 production) while maintaining nor-
mocapnia (PaCO2 ≤ 40 mm Hg). As tidal volume was
reduced during the study, AVCO2R was sufficient to
maintain normocapnia. Animals were weaned from
AVCO2R beginning after day 2 until only 1 animal still
required AVCO2R after day 4. This animal, however,
was weaned from AVCO2R over days 5 to 7 and was
off AVCO2R by the end of day 7.
Changes in peak inspiratory pressure during
AVCO2R, compared with the sham group, are shown in
Fig 5. Incremental ventilator reductions in rate and
tidal volume decreased peak inspiratory pressure by
41% as compared with baseline (P < .05) while main-
taining normocapnia (day 3). Peak inspiratory pres-
sures in AVCO2R animals were significantly lower than
in sham animals throughout the study. AVCO2R also
allowed significant reductions in minute ventilation as
Fig 3. AVCO2R blood flow (Qb) and cardiac output remained
stable while AVCO2R flow ranged from 821.4 ± 55.4 mL/min
to 970.2 ± 45.1 mL/min and averaged 869.9 ± 23.2 mL/min
or 13.2% ± 0.7% of the cardiac output.
Fig 4. CO2 removal and resultant PaCO2 on AVCO2R. The
decreasing n is due to animals improving and weaning from
AVCO2R. Six of 8 animals were off AVCO2R by the end of
day 3. For the 1 animal that required AVCO2R to day 7,
AVCO2R flow was weaned during days 5 to 7. ARDS, Adult
respiratory distress syndrome.
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compared with the sham group (Fig 6). Significant
reductions were seen at days 1 to 4 (P < .05). At 48
hours, AVCO2R allowed significant reductions com-
pared with onset of ARDS entry criteria (PAO2/FIO2
ratio < 200) in minute ventilation (12.4 ± 1.5 to 6.5 ±
0.6 L/min), tidal volume (398.8 ± 42.1 to 274.0 ± 7.5
mL), peak inspiratory pressure (23.4 ± 2.9 to 18.8 ± 0.8
cm H2O), respiratory rate (24.0 ± 1.7 to 17.0 ± 2.0
breaths/min), and FIO2 (0.88 to 0.35 ± 0.1) while nor-
mocapnia was maintained. Fig 7 shows improvement
in the PaO2/FIO2 ratio once AVCO2R was used, allow-
ing a reduction in FIO2 commensurate with an improve-
ment in arterial oxygenation. The PaO2/FIO2 ratio
improved from 151.5 ± 40.0 at the introduction of
AVCO2R to more than 200 over 36 hours, with further
improvement to more than 300 (320.0 ± 17.8) by 72
hours. The PaO2/FIO2 ratio in the 3 surviving sham ani-
mals improved in a similar pattern.
Discussion
Hickling, Henderson, and Jackson18 first published
retrospective data on 50 patients with severe ARDS
managed with permissive hypercapnia, significantly
lowering the hospital mortality rate predicted by the
APACHE* II scores (26.4% vs 53.3%, P = .004).11
Amato and colleagues19 compared “protective ventila-
tion” at 6 mL/kg tidal volume with “conventional” ven-
tilation at 12 mL/kg tidal volume in patients with
ARDS. Protective ventilation allowed 66% of the
patients to be weaned from ventilators compared with
29% with conventional ventilation; clinical barotrauma
was 7% versus 42%, and hospital mortality was 38%
versus 71%. Despite early reported success, the impact
of “protective lung ventilation” on patients’ outcomes
needed clarification because some studies reported an
improved outcome whereas several randomized con-
trolled studies could not demonstrate significant bene-
ficial effects.20-22 The recent National Institutes of
Health/National Heart, Lung, and Blood Institute
(NIH/NHLBI) ARDS Clinical Network on Ventilator
Management of ALI and ARDS study of low tidal vol-
ume (a randomized, controlled trial on 12 vs 6 mL/kg
tidal volume) was terminated after 861 patients
because the outcome of patients in the low tidal volume
group was significantly improved by approximately
25%.23 Likewise, the American Thoracic Society
International Consensus Conference on Ventilator-
Associated Lung Injury in ARDS recently reaffirmed
that ventilator-induced lung injury is an important
determinant of mortality in patients with ARDS.24 Our
study was not designed to evaluate the strategy of low
tidal volume with “permissive hypercapnia” versus
AVCO2R. Instead, the goal of this particular study was
to compare the strategy of “protocol-driven” pressure-
limited ventilation versus AVCO2R. We plan future
studies to specifically evaluate the low tidal volume
pressure-limited ventilation at different levels of hyper-
capnia (60s vs 80s), with and without blood pH nor-
malization versus AVCO2R.
Fig 5. Reduction in peak inspiratory pressure during
AVCO2R. Incremental ventilator reductions in rate and tidal
volume decreased peak inspiratory pressure by 41% as com-
pared with baseline (P < .05) while maintaining normocapnia
(day 3). Peak inspiratory pressure in AVCO2R animals was
consistently less than in sham animals throughout the study.
The decreasing n is due to animals being weaned from
mechanical ventilation (AVCO2R) or dying of respiratory
failure (sham).
Fig 6. Reduction in minute ventilation during AVCO2R as
compared with sham. Significant reductions were made at
days 1 to 4 (*P < .05).
*Acute Physiology and Chronic Health Evaluation.
ECMO provides complete gas exchange and
improves survival in neonates,25 pediatric patients,26,27
and selected adult patients.28,29 More than 15,000 cases
of ECMO, to date, reveal an 81% survival in neonates,
49% in children, and 38% in adults in patient popula-
tions estimated to have more than an 80% mortality.30
ECMO, however, involves intensive monitoring, high
cost in labor and equipment, and frequent complica-
tions.31 To eliminate the need for an extracorporeal cir-
cuit, Mortensen and Berry32 developed an intravenacav-
al device (IVOX) designed to provide oxygenation and
CO2 removal. Intracorporeal membrane oxygenation
and CO2 removal provide 30% of CO2 removal to sig-
nificantly reduce the ventilatory requirements due to
surface area limitations.33 The technique, although
innovative, was unsuccessful because clinical trials
revealed a surface area limitation for sufficient gas
exchange34 and no impact on mortality.
AVCO2R was developed to minimize the foreign sur-
face interactions and blood element shear stress (inher-
ent in an extracorporeal circuit with a pump) and allow
a gas exchange membrane of sufficient surface area for
total CO2 removal.35-37 Recent developments in com-
putational fluid dynamics have led to newly designed,
low-resistance oxygenators.38 We coupled such a low-
resistance gas exchanger with percutaneous arterial and
venous cannulas selected for the flow ranges necessary
for total CO2 removal for the treatment of respiratory
failure.15 The extremely low resistance of the circuit
and gas exchanger (<10 mm Hg) allowed a blood flow
of up to 14% of the cardiac output at a mean arterial
blood pressure in the 90 mm Hg range. We achieved
approximately 970 mL/min of flow with a transdevice
resistance consistently less than 10 mm Hg, to achieve
near total CO2 removal.
To evaluate the effect of our newly designed
AVCO2R circuit on regional organ/tissue perfusion at
varying levels of AVCO2R flow, we injected colored
microspheres in a conscious adult sheep. At up to a
25% arteriovenous shunt, vital organ perfusion (brain,
heart, kidney, mesentery) was well maintained within
80% of baseline in the conscious animal. We conclude
that organ blood flow distribution is only mildly affect-
ed with an arteriovenous shunt of sufficient magnitude
to allow total CO2 removal.39 To determine hemody-
namic tolerability of prolonged AVCO2R, we subjected
adult sheep to a severe smoke inhalation injury to
induce ARDS and then applied AVCO2R at sufficient
shunt flow for total CO2 removal to evaluate the effect
of sustained AVCO2R flow on critical hemodynamic
variables over 7 days.40 Our data confirmed that despite
up to a 25% cardiac shunt through the AVCO2R circuit
for 7 days, there was no instability in the hemodynam-
ic profile, specifically heart rate, cardiac output, mean
arterial pressure, pulmonary artery pressure, or
AVCO2R flow.
To establish a clinically relevant model of severe re-
spiratory failure in adult sheep, we developed a smoke
dose-dependent smoke/burn model of ARDS of pre-
dictable severity.16 We found an inhalation injury of 36
breaths of smoke coupled with a 40% (20% each flank)
third-degree cutaneous burn could create an LD50
model to allow evaluation of the utility of AVCO2R
during ARDS.
Percutaneous AVCO2R involves much simpler moni-
toring and maintenance than conventional ECMO. The
simplicity of percutaneous femoral vessel cannulation
with relatively small cannulas, the substantially
reduced foreign body blood interface, and elimination
of the shear forces of a blood pump all greatly simpli-
fy the extracorporeal circuit with the potential for
decreased complications. The AVCO2R circuit does not
eliminate the gas exchange device (oxygenator) and so
still requires systemic heparinization with the potential
for bleeding complications. In the laboratory setting,
the higher heparin doses (ACT 300-500 seconds) were
easier to maintain over the 7-day study than tightly
titrated lower ACTs. We41 have presented our data on
the use of heparin-coated AVCO2R circuits to allow
decreased dosing of systemic heparin to ACTs of less
than 200 seconds. Although the sheep in this 7-day out-
comes study demonstrated no hemodynamic instability
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Fig 7. PaO2/FIO2 after smoke inhalation and cutaneous flame
burn injury and after placement of AVCO2R. Entry criteria
(PaO2/FIO2 < 200) was met at 48 hours (194.8 ± 25.9). At the
time AVCO2R was initiated, PaO2/FIO2 was 151.5 ± 40.0.
After 36 hours, PaO2/FIO2 had improved to more than 200,
and after 72 hours PaO2/FIO2 was more than 300 (320.0 ±
17.8). The 3 (of 8) surviving sham animals improved in a
similar pattern.
during AVCO2R, patients with concomitant cardiac dis-
ease or pre-existing hemodynamic instability may not
tolerate the 11% to 14% arteriovenous shunt. Our
upcoming prospective randomized clinical trials are
designed to address these issues. 
This current prospective randomized outcomes
study required 2946 total animal-hours of bedside
critical care and 696 total hours of AVCO2R in a lab-
oratory setting. Although “unblinded” for obvious
reasons, the fact that all management was directed by
a study algorithm with 90% compliance compares
very favorably with other algorithm-directed ventila-
tor management studies.42 Only one AVCO2R animal
experienced minor bleeding (relieved with pressure)
from the incision site at the neck. Our technique of
AVCO2R still requires systemic anticoagulation with
heparin and, therefore, imposes additional risks of
bleeding. Heparin anticoagulation alone may improve
outcome of smoke inhalation injury if administered
immediately on injury.43 However, this study used
clinical entry criteria for ARDS (PaO2/FIO2 < 200 mm
Hg). Therefore, 40 to 48 hours were required for
ARDS to develop in these animals as seen clinically.
This late in the course of ARDS, heparin alone con-
tributes little to improving outcome.44 Future devel-
opments of coated circuits and gas exchangers may
decrease the blood/foreign surface interactions and
decrease the need for anticoagulation.
Percutaneous AVCO2R in combination with low-fre-
quency mechanical ventilation allowed significant
reductions in minute ventilation, peak inspiratory pres-
sures, and ventilator-dependent days, while achieving a
significant improvement in survival in our ovine model
of ARDS. The improved results in survival and ventila-
tor-free/dependent days may be directly related to the
reduction in tidal volume and airway pressures.
Because the sham animals were managed to match the
blood gas values of AVCO2R animals, resultant blood
gases were similar in both groups. As AVCO2R allowed
immediate reductions in minute ventilation and peak
inspiratory pressure, lung rest was achieved, presum-
ably contributing to the improved survival.
Along with the decreased ventilatory requirements
associated with the use of AVCO2R, there was a con-
comitant improvement in arterial oxygenation.45 As
shown in Fig 7, similar improvement in PaO2/FIO2
ratio was seen among surviving animals—all 8
AVCO2R animals but only 3 of 8 sham animals. As
described by Bone and coworkers,46 the PaO2/FIO2
ratio remains a reliable predictor of survival from
ARDS, regardless of the therapeutic modality. Most
interestingly, AVCO2R, a treatment modality that
reduces ventilatory requirements by extracorporeal
removal of CO2 manifested improved survival with
improvements in PaO2/FIO2 ratio. This improvement
in arterial oxygenation with AVCO2R is likely due to
three separate effects. With resolution of noncardio-
genic pulmonary edema associated with the lung
injury, one would expect a decrement in the right-to-
left shunt fraction. Second, the use of AVCO2R
improves the central mixed venous oxygen tensions,
due to the admixture of well-oxygenated blood from
AVCO2R with the venous return to the right atrium.
Finally, AVCO2R allows the use of low peak airway
pressures and tidal volumes to accomplish gas
exchange, improving the ventilation/perfusion rela-
tionship and preventing further barotrauma/volutrau-
ma from mechanical ventilation. Our data indicate
that the PaO2 in AVCO2R animals was successfully
managed above 60 mm Hg by adjusting FIO2 and
maintaining positive end-expiratory pressure at 5 cm
H2O. Thus, near-apneic oxygenation coupled with
lung rest proved to be sufficient for oxygen exchange
even in the presence of ARDS. Percutaneous
AVCO2R, therefore, can be an effective treatment,
not only for CO2 retention syndromes, but also dur-
ing ARDS with poor oxygenation.
We have reported the application of AVCO2R in 5
patients with unresponsive severe ARDS and CO2
retention as a safety and feasibility study.47 Via percu-
taneous access, AVCO2R achieved approximately 70%
CO2 removal and allowed decreased barotrauma/volu-
trauma without hemodynamic compromise. All 5
patients were successfully cannulated for AVCO2R at
the bedside and completed the 72-hour trial. Three of
the 5 patients were eventually discharged from the hos-
pital. On the basis of our favorable initial patient expe-
rience and this prospective randomized outcomes study
in sheep, we plan three prospective randomized ARDS
trials using percutaneous AVCO2R in humans: (1)
smoke/burn-induced ARDS in children; (2) ARDS in
adults; and (3) acute CO2 retention syndromes in
adults. The control arm of each of these studies will use
the gentle ventilation strategies as outlined in the recent
NIH/NHLBI ARDS network trial.
In conclusion, in a prospective randomized outcomes
study of ARDS in sheep, AVCO2R significantly
reduced minute ventilation and peak airway pressure
during mechanical ventilation for ARDS, significantly
increased ventilator-free days and decreased ventilator-
dependent days, and significantly improved survival. In
addition to the clinical trials outlined, we plan further
studies on optimization of gas exchange during
AVCO2R and studies on pathophysiology of ARDS.
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Discussion
Dr Robert H. Bartlett (Ann Arbor, Mich). If you have ever
tried to do an acute animal experiment for 7 hours, you know
how difficult it is, and you have some appreciation of the
work that was involved in doing acute animal experiments for
7 days. Very few studies have been conducted on any type of
prolonged extracorporeal support (or, for that matter, ventila-
tor support) in animals with acute lung injury. I dare say they
have all been done by either Ted Kolobow or Jay
Zwischenberger, and you just heard the best one done to date. 
The reason these studies are so rare is they are so hard to
do. You have to have a way of taking care of sick animals
for days at a time, standardize the model, standardize every-
thing except the intervention, and characterize the interven-
tion. I do not have to describe to you how difficult it is. This
is simply a beautiful study, which addresses a couple of very
interesting questions.
We always teach the residents when they are managing
severe respiratory failure to think about CO2 clearance and
oxygenation as very different issues. They overlap, to be sure,
but oxygenation is a matter of alveolar inflation matching
perfusion. CO2 removal is a matter of breathing. If you just
run around with your mouth open, you can oxygenate your
blood. You breathe in and out just to clear carbon dioxide, and
this study emphasizes that issue. 
Dr Zwischenberger has used this novel technology to study
the effect of mechanical ventilation on acute lung injury. This
technique is simple. We want to know something about the
clinical application of it. 
Regarding mechanical ventilation in normal animals, there
are a host of studies. The first one that I know of is by
Greenfield and Ebert. They showed that if normal dogs are
ventilated with a moderate inspiratory pressure (30 cm H2O),
severe lung injury will result in about 2 days. 
Many studies since then by Kolobow, Dreyfus, West, and
many others have shown that even moderate stretch injury to
the lung causes severe lung injury. 
A lot of human studies have shown that mechanical venti-
lation in lung-injured persons adds to the injury in a signifi-
cant way. The first of these studies was by Gattinoni, demon-
strating with computed tomographic scan that the volume of
lung to be ventilated in an ARDS patient is much smaller than
one might think, judging by the size of the patient. Studies by
Hickling and Amato showed that if overdistention is avoided,
survival outcome is better. Recently a large study done by the
NIH/NHLBI ARDS network showed the same thing. If the
lung is stretched even moderately in patients with severe re-
spiratory failure, it adds significantly to the mortality. Of
course, the ECMO studies in children, infants, and adults
show the same thing. If the patient is simply taken off the
ventilator or the settings are reduced to low settings, the out-
come will be much better than if the ventilatory practices that
have been taught for the past 35 years are used. 
I congratulate Dr Zwischenberger on the quality of the
study. I have 2 questions. 
of respiratory failure, such as tumor necrosis factor α, and we
have significant preliminary data that this strategy does
decrease the flame and the fuel that fire ARDS. 
We have also noted that CO2 homeostasis at the alveolar
level may decrease macrophage activation of inflammatory
mediators and influx of neutrophils in the inflammatory cel-
lular response. 
Last, at the alveolar level, achieving CO2 homeostasis may
allow decreased transfer of fluid or influx of fluid in the alve-
olus, which causes an abnormality of compliance. Decreasing
aquaporin activity may contribute to this finding. 
These competing theories are under investigation. The one
we know we are able to achieve is decreasing ventilator-
induced lung injury. Because of AVCO2R technology and the
fact that we have been able to demonstrate improved survival
in animals and feasibility in human beings, we are now
embarking on the 3 clinical trials that were described. Thanks
to available funding, we have started a multicenter clinical
trial on ARDS in children associated with burn injury. We
have also appealed to funding agencies to do a multicenter
clinical trial in adults. I am trying to avoid the use of com-
mercial or entrepreneurial funding, so I am focusing on peer-
reviewed sources to accomplish these trials. 
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You referred briefly to clinical application, but I would like
to know where those studies stand and what you plan to do
with them. 
Second (and to me much more interesting), on the basis of this
information, why do you think that conventional mechanical
ventilation, as you used in this study, caused higher mortality? 
Dr Zwischenberger. You just heard the best 3-minute syn-
opsis on respiratory failure I have ever been subjected to.
Since Dr Bartlett has been my mentor for the past 20 years, I
want to thank him for interesting this young investigator in
the problem of respiratory failure. 
What I can say is that lung protective strategies of ventilator
management have been emphasized by this study. By removing
CO2, we are able to dramatically decrease the pressure and vol-
ume of ventilation and therefore impose even more lung pro-
tection. At first assessment, I believe the primary source of ame-
lioration of the lung injury is the fact that we decrease peak
inspiratory pressure, decrease mean airway pressure, and
decrease minute ventilation. However, as we thought about res-
piratory failure, we were enthralled by the idea that perhaps
homeostasis of CO2 may have profound effects on the patho-
physiology of ARDS. That is where our primary interest is now
focusing. One option is to decrease the inflammatory mediators
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